JW Holdings forges strategic tie-up with Japanese pharmaceutical firm

Published: 2013-07-10 07:00:00

Updated: 2013-07-10 07:00:00

JW Holdings said Monday that it has forged a strategic alliance with a leading Japanese drug firm in an effort to strengthen its global competitiveness.

Under the contract with Sanwa Kagaku Kenkyusho, an affiliated company of Japan’s Suzuken Group, JW Holdings said both companies will co-devel...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK